Symbols / PEPG $5.23 -2.24%
PEPG Chart
About
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 361.47M |
| Enterprise Value | 238.31M | Income | -89.66M | Sales | — |
| Book/sh | 2.14 | Cash/sh | 2.15 | Dividend Yield | — |
| Payout | 0.00% | Employees | 56 | IPO | — |
| P/E | — | Forward P/E | -4.28 | PEG | — |
| P/S | — | P/B | 2.44 | P/C | — |
| EV/EBITDA | -2.58 | EV/Sales | — | Quick Ratio | 11.74 |
| Current Ratio | 11.94 | Debt/Eq | 11.53 | LT Debt/Eq | — |
| EPS (ttm) | -2.12 | EPS next Y | -1.22 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -36.03% |
| ROE | -67.39% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 69.12M |
| Shs Float | 36.97M | Short Float | 4.95% | Short Ratio | 4.33 |
| Short Interest | — | 52W High | 7.80 | 52W Low | 0.88 |
| Beta | 1.87 | Avg Volume | 729.31K | Volume | 5.33K |
| Target Price | $10.86 | Recom | Strong_buy | Prev Close | $5.35 |
| Price | $5.23 | Change | -2.24% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.86
Mean price target
2. Current target
$5.21
Latest analyst target
3. DCF / Fair value
$-12.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.21
Low
$3.00
High
$20.00
Mean
$10.86
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | Oppenheimer | — → Outperform | $15 |
| 2026-02-18 | main | Guggenheim | Buy → Buy | $7 |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-09-30 | main | Wedbush | Outperform → Outperform | $8 |
| 2025-09-25 | main | Stifel | Buy → Buy | $12 |
| 2025-09-25 | main | Wedbush | Outperform → Outperform | $9 |
| 2025-09-25 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-24 | reit | Guggenheim | Buy → Buy | $6 |
| 2025-09-09 | init | Guggenheim | — → Buy | $6 |
| 2025-05-29 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-01-30 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-12-16 | down | B of A Securities | Neutral → Underperform | $3 |
| 2024-11-18 | main | B of A Securities | Neutral → Neutral | $6 |
| 2024-11-08 | main | Wedbush | Outperform → Outperform | $12 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-07-31 | reit | Wedbush | Outperform → Outperform | $20 |
- $PEPG stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 13 Mar 2026 19
- How much upside is left in PepGen (PEPG)? Wall Street analysts think 75.44% - MSN ue, 17 Mar 2026 10
- FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial - Sahm Fri, 13 Mar 2026 15
- PepGen stock slides on FDA partial hold (PEPG:NASDAQ) - Seeking Alpha hu, 05 Mar 2026 08
- Boxer Capital Management LLC Invests $1.16 Million in PepGen, Inc. $PEPG - MarketBeat Sun, 15 Mar 2026 11
- PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill Wed, 11 Mar 2026 07
- PepGen DM1 drug shows high splicing correction in Phase 1 data - Stock Titan Wed, 04 Mar 2026 21
- Commodore Capital LP Invests $10.89 Million in PepGen, Inc. $PEPG - MarketBeat Sun, 15 Mar 2026 09
- PepGen CEO James McArthur joins Miami healthcare fireside chat March 10 - Stock Titan ue, 03 Mar 2026 08
- PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines (NASDAQ:PEPG) - Seeking Alpha hu, 05 Mar 2026 08
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG - Sahm hu, 12 Mar 2026 07
- PepGen (PEPG) CTO receives 135,000 options and 34,557 RSUs in grant - Stock Titan Mon, 02 Mar 2026 08
- $PEPG stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- PepGen (PEPG) CEO share sale covers RSU tax withholding obligations - Stock Titan Fri, 06 Mar 2026 21
- PepGen (PEPG) CFO’s 2,084-share automatic sale covers RSU tax withholding - Stock Titan Fri, 06 Mar 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1879 | 11709 | — | Sale at price 6.23 - 6.29 per share. | STRECK PAUL | Officer | — | 2026-03-04 00:00:00 | D |
| 1 | 5275 | 32876 | — | Sale at price 6.23 - 6.32 per share. | MCARTHUR JAMES G | Chief Executive Officer | — | 2026-03-04 00:00:00 | D |
| 2 | 2084 | 12988 | — | Sale at price 6.23 - 6.32 per share. | DONNELLY NOEL | Chief Financial Officer | — | 2026-03-04 00:00:00 | D |
| 3 | 30717 | — | — | Stock Award(Grant) at price 0.00 per share. | VITTIGLIO JOSEPH D | Officer | — | 2026-02-27 00:00:00 | D |
| 4 | 50300 | — | — | Stock Award(Grant) at price 0.00 per share. | STRECK PAUL | Officer | — | 2026-02-27 00:00:00 | D |
| 5 | 187688 | — | — | Stock Award(Grant) at price 0.00 per share. | MCARTHUR JAMES G | Chief Executive Officer | — | 2026-02-27 00:00:00 | D |
| 6 | 76793 | — | — | Stock Award(Grant) at price 0.00 per share. | DONNELLY NOEL | Chief Financial Officer | — | 2026-02-27 00:00:00 | D |
| 7 | 34557 | — | — | Stock Award(Grant) at price 0.00 per share. | KASRAIAN KASRA PH.D. | Chief Technology Officer | — | 2026-02-27 00:00:00 | D |
| 8 | 35000 | — | — | Stock Award(Grant) at price 0.00 per share. | VITTIGLIO JOSEPH D | Officer | — | 2025-12-08 00:00:00 | D |
| 9 | 200000 | 924000 | — | Purchase at price 4.62 per share. | OXFORD SCIENCES ENTERPRISES PLC | Unknown | — | 2025-09-30 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.01 | 0.21 | 0.21 |
| NormalizedEBITDA | -88.47M | -92.49M | -83.92M | -67.81M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -89.66M | -89.98M | -78.63M | -69.10M |
| ReconciledDepreciation | 5.14M | 5.25M | 850.00K | 493.00K |
| EBITDA | -88.47M | -92.49M | -83.92M | -67.81M |
| EBIT | -93.61M | -97.74M | -84.77M | -68.30M |
| NetInterestIncome | 4.02M | 7.14M | 6.40M | 2.79M |
| InterestIncome | 4.02M | 7.14M | 6.40M | 2.79M |
| NormalizedIncome | -89.66M | -89.98M | -78.63M | -69.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -89.66M | -89.98M | -78.63M | -69.10M |
| TotalExpenses | 93.61M | 97.74M | 84.77M | 68.30M |
| TotalOperatingIncomeAsReported | -93.61M | -97.74M | -84.77M | -68.30M |
| DilutedAverageShares | 42.22M | 31.58M | 23.80M | 23.71M |
| BasicAverageShares | 42.22M | 31.58M | 23.80M | 23.71M |
| DilutedEPS | -2.12 | -2.85 | -3.30 | -2.91 |
| BasicEPS | -2.12 | -2.85 | -3.30 | -2.91 |
| DilutedNIAvailtoComStockholders | -89.66M | -89.98M | -78.63M | -69.10M |
| NetIncomeCommonStockholders | -89.66M | -89.98M | -78.63M | -69.10M |
| OtherunderPreferredStockDividend | -196.00K | |||
| NetIncome | -89.66M | -89.98M | -78.63M | -69.10M |
| NetIncomeIncludingNoncontrollingInterests | -89.66M | -89.98M | -78.63M | -69.10M |
| NetIncomeContinuousOperations | -89.66M | -89.98M | -78.63M | -69.10M |
| TaxProvision | 49.00K | -617.00K | 73.00K | 3.71M |
| PretaxIncome | -89.61M | -90.60M | -78.55M | -65.40M |
| OtherIncomeExpense | -11.00K | -1.00K | -187.00K | 110.00K |
| OtherNonOperatingIncomeExpenses | -11.00K | -1.00K | -187.00K | 110.00K |
| NetNonOperatingInterestIncomeExpense | 4.02M | 7.14M | 6.40M | 2.79M |
| InterestIncomeNonOperating | 4.02M | 7.14M | 6.40M | 2.79M |
| OperatingIncome | -93.61M | -97.74M | -84.77M | -68.30M |
| OperatingExpense | 93.61M | 97.74M | 84.77M | 68.30M |
| ResearchAndDevelopment | 71.04M | 76.48M | 68.13M | 54.08M |
| SellingGeneralAndAdministration | 22.57M | 21.26M | 16.64M | 14.22M |
| GeneralAndAdministrativeExpense | 22.57M | 21.26M | 16.64M | 14.22M |
| OtherGandA | 22.57M | 21.26M | 16.64M | 14.22M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 68.87M | 32.62M | 23.82M | 23.71M |
| ShareIssued | 68.87M | 32.62M | 23.82M | 23.71M |
| TotalDebt | 17.00M | 18.66M | 20.10M | 24.53M |
| TangibleBookValue | 147.44M | 118.62M | 108.42M | 179.63M |
| InvestedCapital | 147.44M | 118.62M | 108.42M | 179.63M |
| WorkingCapital | 138.32M | 107.06M | 95.15M | 167.25M |
| NetTangibleAssets | 147.44M | 118.62M | 108.42M | 179.63M |
| CapitalLeaseObligations | 17.00M | 18.66M | 20.10M | 24.53M |
| CommonStockEquity | 147.44M | 118.62M | 108.42M | 179.63M |
| PreferredStockEquity | 165.18M | |||
| TotalCapitalization | 147.44M | 118.62M | 108.42M | 179.63M |
| TotalEquityGrossMinorityInterest | 147.44M | 118.62M | 108.42M | 179.63M |
| StockholdersEquity | 147.44M | 118.62M | 108.42M | 179.63M |
| GainsLossesNotAffectingRetainedEarnings | 11.00K | 23.00K | 34.00K | -81.00K |
| OtherEquityAdjustments | 11.00K | 23.00K | 34.00K | -81.00K |
| RetainedEarnings | -361.12M | -271.46M | -181.48M | -102.86M |
| AdditionalPaidInCapital | 508.54M | 390.06M | 289.87M | 282.57M |
| CapitalStock | 7.00K | 3.00K | 2.00K | 2.00K |
| CommonStock | 7.00K | 3.00K | 2.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 26.46M | 32.26M | 34.63M | 37.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 13.82M | 15.57M | 17.10M | 18.98M |
| DerivativeProductLiabilities | 0.00 | 226.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 13.82M | 15.57M | 17.10M | 18.98M |
| LongTermCapitalLeaseObligation | 13.82M | 15.57M | 17.10M | 18.98M |
| CurrentLiabilities | 12.65M | 16.70M | 17.53M | 18.83M |
| CurrentDebtAndCapitalLeaseObligation | 3.19M | 3.09M | 3.00M | 5.55M |
| CurrentCapitalLeaseObligation | 3.19M | 3.09M | 3.00M | 5.55M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.66M | 3.62M | 2.37M | 2.44M |
| PayablesAndAccruedExpenses | 4.80M | 9.98M | 12.16M | 10.84M |
| CurrentAccruedExpenses | 3.97M | 8.23M | 11.15M | 6.90M |
| Payables | 822.00K | 1.75M | 1.00M | 3.94M |
| TotalTaxPayable | 0.00 | 2.57M | 0.00 | |
| AccountsPayable | 822.00K | 1.75M | 1.00M | 1.36M |
| TotalAssets | 173.91M | 150.88M | 143.05M | 217.44M |
| TotalNonCurrentAssets | 22.94M | 27.12M | 30.37M | 31.36M |
| OtherNonCurrentAssets | 1.92M | 1.97M | 1.99M | 1.47M |
| NetPPE | 21.02M | 25.15M | 28.38M | 29.88M |
| AccumulatedDepreciation | -3.91M | -3.05M | -1.57M | -389.00K |
| GrossPPE | 24.93M | 28.19M | 29.96M | 30.27M |
| Leases | 23.62M | 26.55M | ||
| ConstructionInProgress | 20.00K | 96.00K | 69.00K | 1.13M |
| OtherProperties | 23.16M | 26.54M | 28.44M | 2.42M |
| MachineryFurnitureEquipment | 1.76M | 1.56M | 1.45M | 171.00K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 150.96M | 123.76M | 112.68M | 186.08M |
| OtherCurrentAssets | 2.51M | 3.57M | 2.27M | 4.33M |
| PrepaidAssets | 2.35M | |||
| Receivables | 58.00K | 4.74M | ||
| OtherReceivables | 58.00K | 4.74M | ||
| CashCashEquivalentsAndShortTermInvestments | 148.46M | 120.19M | 110.41M | 181.75M |
| OtherShortTermInvestments | 87.94M | 70.77M | 29.63M | 0.00 |
| CashAndCashEquivalents | 60.51M | 49.42M | 80.77M | 181.75M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -81.90M | -82.87M | -71.60M | -63.02M |
| IssuanceOfCapitalStock | 108.10M | 86.78M | 0.00 | 114.27M |
| CapitalExpenditure | -264.00K | -497.00K | -2.60M | -3.75M |
| IncomeTaxPaidSupplementalData | 82.00K | 71.00K | 2.70M | 0.00 |
| EndCashPosition | 62.06M | 50.97M | 82.32M | 183.22M |
| BeginningCashPosition | 50.97M | 82.32M | 183.22M | 134.37M |
| EffectOfExchangeRateChanges | -16.00K | -62.00K | 286.00K | -316.00K |
| ChangesInCash | 11.11M | -31.29M | -101.19M | 49.17M |
| FinancingCashFlow | 107.98M | 88.75M | -189.00K | 112.19M |
| CashFlowFromContinuingFinancingActivities | 107.98M | 88.75M | -189.00K | 112.19M |
| NetOtherFinancingCharges | -413.00K | -511.00K | -442.00K | -2.70M |
| ProceedsFromStockOptionExercised | 292.00K | 2.48M | 253.00K | 623.00K |
| NetPreferredStockIssuance | 0.00 | 149.04M | ||
| PreferredStockIssuance | 0.00 | 149.04M | ||
| NetCommonStockIssuance | 108.10M | 86.78M | 0.00 | 114.27M |
| CommonStockIssuance | 108.10M | 86.78M | 0.00 | 114.27M |
| InvestingCashFlow | -15.23M | -37.67M | -32.00M | -3.75M |
| CashFlowFromContinuingInvestingActivities | -15.23M | -37.67M | -32.00M | -3.75M |
| NetInvestmentPurchaseAndSale | -14.97M | -37.17M | -29.40M | 0.00 |
| SaleOfInvestment | 79.00M | 108.00M | 0.00 | |
| PurchaseOfInvestment | -93.97M | -145.17M | -29.40M | 0.00 |
| NetPPEPurchaseAndSale | -264.00K | -497.00K | -2.60M | -3.75M |
| PurchaseOfPPE | -264.00K | -497.00K | -2.60M | -3.75M |
| OperatingCashFlow | -81.64M | -82.37M | -69.00M | -59.27M |
| CashFlowFromContinuingOperatingActivities | -81.64M | -82.37M | -69.00M | -59.27M |
| ChangeInWorkingCapital | -6.22M | -5.25M | 1.95M | 4.51M |
| ChangeInOtherCurrentLiabilities | -3.09M | -3.00M | -1.17M | -2.02M |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | -4.20M | -941.00K | 1.05M | 4.12M |
| ChangeInAccruedExpense | -3.27M | -1.66M | 1.42M | 5.53M |
| ChangeInPayable | -935.00K | 722.00K | -369.00K | -1.41M |
| ChangeInAccountPayable | -935.00K | 722.00K | -369.00K | -1.41M |
| ChangeInPrepaidAssets | 1.07M | -1.30M | 2.06M | -1.78M |
| ChangeInReceivables | 26.00K | 4.18M | -4.34M | |
| OtherNonCashItems | 70.00K | 134.00K | ||
| StockBasedCompensation | 10.61M | 11.46M | 7.05M | 4.76M |
| AssetImpairmentCharge | 701.00K | 0.00 | ||
| AmortizationOfSecurities | -2.21M | -3.92M | -220.00K | 0.00 |
| DepreciationAmortizationDepletion | 5.14M | 5.25M | 850.00K | 493.00K |
| DepreciationAndAmortization | 5.14M | 5.25M | 850.00K | 493.00K |
| AmortizationCashFlow | 3.75M | 3.75M | -334.00K | 0.00 |
| AmortizationOfIntangibles | 3.75M | 3.75M | -334.00K | 0.00 |
| Depreciation | 1.40M | 1.50M | 1.18M | 493.00K |
| OperatingGainsLosses | 76.00K | 196.00K | ||
| GainLossOnInvestmentSecurities | -58.00K | 196.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 134.00K | ||
| NetIncomeFromContinuingOperations | -89.66M | -89.98M | -78.63M | -69.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PEPG
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|